KYMR says it accelerated STAT6 trial enrollment and outlined expansion plans
KYMR highlighted accelerated enrollment in pivotal STAT6 trials for atopic dermatitis and asthma, citing a strong safety profile. It also plans aggressive expansion across indications, with a focus on pediatric populations, and continued IRF5 program advancement.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.